Individualized extension of pegylated interferon plus ribavirin therapy for recurrent hepatitis C genotype 1b after living-donor liver transplantation

Transplantation

Volumn 90, Issue 6, 2010, Pages 661-665

  Ueda, Yoshihide ^a   Takada, Yasutsugu ^a   Marusawa, Hiroyuki ^a   Egawa, Hiroto ^a   Uemoto, Shinji ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Extended treatment; Hepatitis C; Liver transplantation; Pegylated interferon; Ribavirin

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2B; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN; STEROID; TACROLIMUS; VIRUS RNA; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER TRANSPLANTATION; LIVING DONOR; MALE; NEUTROPENIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RECURRENT INFECTION; SPINAL CORD DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; DRUG COMBINATION; GENETICS; HEPACIVIRUS; IMMUNOLOGY; LIVER; MIDDLE AGED; PATHOLOGY; RECURRENT DISEASE; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; LIVER; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RECURRENCE; RIBAVIRIN;

EID: 77957252221     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181d2bfca     Document Type: Article

References (22)

1. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decreasein patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202.
2. Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted ActiononViral Hepatitis (EUROHEP) Group. Gastroenterology 1999; 117: 619.
3. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889.
4. Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl 2003; 9: S28.
5. Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250.
6. Sanchez-Fueyo A, Restrepo JC, Quinto L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002; 73: 56.
7. Velidedeoglu E, Mange KC, Frank A, et al. Factors differentially correlated with the outcome of liver transplantation in hcv+ and HCV\recipients. Transplantation 2004; 77: 1834.
8. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 2000; 32: 673.
9. Gordon FD, Kwo P, Vargas HE. Treatment of hepatitis C in liver transplant recipients. Liver Transpl 2009; 15: 126.
10. Terrault NA. Hepatitis C therapy before and after liver transplantation. Liver Transpl2008; 14(suppl 2): S58.
11. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274.
12. AkutaN, Suzuki F, HirakawaM, etal. A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: Amino acid substitutions in HCV core region as predictor of sustained virological response. J Med Virol2009; 81: 452.
13. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: Comparing 48 versus 72 weeks of peginter-feron-alfa-2a plus ribavirin. Gastroenterology 2006; 130: 1086.
14. Buti M, Valdes A, Sanchez-Avila F, et al. Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases. Hepatology 2003; 37: 1226.
15. Ide T, Hino T, Ogata K, et al. A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C. Am J Gastroenterol 2009; 104: 70.
16. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology 2007; 46: 1688.
17. Sanchez-Tapias JM, Diago M, Escartin P, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology 2006; 131: 451.
18. Ueda Y, Takada Y, Haga H, et al. Limited benefit of biochemical response to combination therapy for patients with recurrent hepatitis C after living-donor liver transplantation. Transplantation 2008; 85: 855.
19. Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol 1997; 35: 201.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289.
21. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825.
22. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335.